RadnostixINIS +2.73% OCF Yield % is 1.46 as of Jun. 28, 2026, which is 232% above its 10-year median of 0.44. The stock has 3 warning signs investors should review. Among 1,002 Drug Manufacturers companies, Radnostix ranks worse than 61.98% on this metric.
OCF Yield % is calculated as Cash Flow from Operations divided by Market Capitalization. It is a financial solvency ratio that compares the operating cash flow a company is expected to earn against its market value.
Similar to Earnings Yield %, OCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high operating cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
Radnostix OCF Yield % Related Terms
Radnostix OCF Yield % Historical Data
* Premium members only.
The historical data trend for Radnostix's OCF Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Radnostix's OCF Yield %, along with its competitors' market caps and OCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Radnostix OCF Yield % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Radnostix's OCF Yield % distribution charts can be found below:
* The bar in red indicates where Radnostix's OCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Radnostix (INIS) has a OCF Yield % of 1.46 as of Jun. 28, 2026. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on Radnostix and its competitors. This is 232% above median its historical median of 0.44. According to the industry distribution chart, Radnostix ranks #621 out of 1002 companies in the Drug Manufacturers industry, placing it in the top 62%.
Is Radnostix's OCF Yield % too high?
Radnostix's current OCF Yield % of 1.46 is 232% above median its 10-year median of 0.44. The Drug Manufacturers industry median OCF Yield % is 3.61. Radnostix's value of 1.46 is 59.6% below this industry median. Based on the distribution chart, Radnostix ranks #621 out of 1002 companies in the Drug Manufacturers industry, which is below the industry midpoint.
How does Radnostix's OCF Yield % compare to TLPH and IXHL?
According to the Drug Manufacturers industry distribution chart, Radnostix ranks #621 out of 1002 companies for OCF Yield %. This places Radnostix in the lower half of its industry. The industry median OCF Yield % is 3.61. Radnostix's value of 1.46 is 59.6% below this benchmark. While the company's 10-year median is 0.44 vs. the industry median of 3.61, Radnostix has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Yield % for a Drug Manufacturers company?
The median OCF Yield % among Drug Manufacturers companies is 3.61, based on 1,002 companies in the industry. Companies in the top quartile (top 25%) have a OCF Yield % significantly above this median, while those in the bottom quartile fall well below. However, OCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Radnostix's current OCF Yield % of 1.46 is 59.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Yield % mean?
A high OCF Yield % can signal that a stock is expensive relative to its fundamentals. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on Radnostix and its competitors. For the Drug Manufacturers industry, the median OCF Yield % is 3.61 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Radnostix's current OCF Yield % is 1.46, which is 232% above median its own 10-year median of 0.44. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Radnostix stock overvalued right now?
Based on GuruFocus' analysis, Radnostix (INIS) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.05, compared to a current price of $0.07 — trading 43.8% above its estimated fair value. The current OCF Yield % is 1.46, which is 232% above median its 10-year median of 0.44 and 59.6% below the Drug Manufacturers industry median of 3.61. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Yield % calculated?
OCF Yield % is calculated from a company's financial statements. For Radnostix (INIS), the current OCF Yield % is 1.46 as of Jun. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Radnostix Inc manufactures a wide range of radioisotope-focused products used in a variety of medical and industrial applications. The company produces generic sodium iodide I-131 drug product, produces a variety of cobalt-60 products, and is in development to manufacture and sell medical devices for the nuclear medicine industry. Its business consists of five reportable segments, which include: Theranostics Products, Cobalt Products, Calibration & Reference Products, Medical Devices, and Fluorine Products. The majority of the revenue is derived from the Theranostics Products segment, which produces and distributes various isotopically pure radiopharmaceuticals, APIs, and radiochemicals for medical, industrial, and research applications.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
INIS has been successfully added to your 